CRISPR-Cas9 Targeting of Specific Mutations in Lung Cancer With Supporting In Vivo Data

• Optimising CRISPR/Cas9-loaded LNPs as a novel therapeutic strategy to target specific mutations in lung cancer
• Presenting in vitro and in vivo data demonstrating editing efficiency, safety, and the therapeutic potential in preclinical models
• Discussing the translational implications for moving CRISPR-based lung cancer therapies toward the clinic

Speakers:

Simone Carneiro

Group Lead

Ludwig-Maximilians-University Munich